AGGRENOX Drug Patent Profile

When do Aggrenox patents expire, and when can generic versions of Aggrenox launch?

Aggrenox is a drug marketed by Boehringer Ingelheim and is included in one NDA.

The generic ingredient in AGGRENOX is aspirin; dipyridamole. There are twenty-two drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the aspirin; dipyridamole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aggrenox

A generic version of AGGRENOX was approved as aspirin; dipyridamole by BARR on August 14^th, 2009.

Summary for AGGRENOX

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	6
Clinical Trials:	16
Patent Applications:	49
Drug Prices:	Drug price information for AGGRENOX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AGGRENOX
What excipients (inactive ingredients) are in AGGRENOX?	AGGRENOX excipients list
DailyMed Link:	AGGRENOX at DailyMed

See drug prices for AGGRENOX

See drug sales revenues for AGGRENOX

Recent Clinical Trials for AGGRENOX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rutgers, The State University of New Jersey	Phase 3
Oklahoma Medical Research Foundation	N/A
Boehringer Ingelheim	Phase 1

See all AGGRENOX clinical trials

Paragraph IV (Patent) Challenges for AGGRENOX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AGGRENOX	Extended-release Capsules	aspirin; dipyridamole	25 mg and 200 mg	020884	1	2007-02-01

US Patents and Regulatory Information for AGGRENOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	AGGRENOX	aspirin; dipyridamole	CAPSULE, EXTENDED RELEASE;ORAL	020884-001	Nov 22, 1999		DISCN	Yes	No

Expired US Patents for AGGRENOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	AGGRENOX	aspirin; dipyridamole	CAPSULE, EXTENDED RELEASE;ORAL	020884-001	Nov 22, 1999

International Patents for AGGRENOX

See the table below for patents covering AGGRENOX around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	3627423
Chile	2004001252
Germany	10299015
Australia	603146
Hong Kong	14494	MEDICAMENTS CONTAINING DIPYRIDAMOL OR MOPIDAMOL AND O-ACETYLSALICYLIC ACID,OR ITS PHYSIOLOGICALLY COMPATIBLE SALTS,PROCESS FOR THEIR MANUFACTURE AND THEIR USE IN COMBATING THE FORMATION OF THROMBUS
Ireland	60862	Pharmaceutical compositions containing dipyridamole or mopidamol and o-acetylsalicylic acid or the physiologically acceptable salts thereof, processes for preparing them and their use in treating clot formation
Australia	7679587

Supplementary Protection Certificates for AGGRENOX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0257344	C990001	Netherlands		PRODUCT NAME: DIPYRIDAMOL, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AAN- VAARDBAAR ZOUT, EN ACETYLSALICYLZUUR, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AANVAARDBAAR ZOUT,IN EEN GEWICHTSVERHOUDING TUSSEN DIPYRIDAMOL-BESTANDDEEL EN ACETYLSALICYLZUUR-BESTANDDE; NAT. REGISTRATION NO/DATE: RVG 21171 19980713; FIRST REGISTRATION: FR 343 234.9, 560 483.7 19970709
0257344	20/1999	Austria		PRODUCT NAME: DIPYRIDAMOL IN KOMBINATION MIT ACETYLSALICYLSAEURE; NAT. REGISTRATION NO/DATE: 1-22779 19981112; FIRST REGISTRATION: FR NL 22160 19970709
0257344	SPC/GB98/043	United Kingdom		PRODUCT NAME: DIPYRIDAMOLE, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE SALT, AND O-ACETYLSALICYLIC ACID, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY SALT, I.E. ASASANTIN RETARD; REGISTERED: FR NL 22160 19970709; UK 00015/0224 19980512